AusBiotech Gains New Members in Australia's Life Sciences

AusBiotech has always been for its members. Built by our members, to be the national voice of our sector we are proud to support our member's growth and leverage our national convening power to shape policy, foster knowledge sharing, and collaborate to advance life sciences in our country. Together, we work to help our members thrive. 

We've been delighted to announce a number of new AusBiotech members over recent months, including 17 who have joined between July and September this year. This includes: Agriculture Victoria Services Pty Ltd, Atticus Medical Pty Ltd, BlinkLab, CAD-IT Australia, Cambium Bio Limited, Douglas Pharmaceuticals Ltd, Evaluate, Evithé Biotechnology, EZZ Life Science Holdings Limited, Global Pharma Solutions, JAG Process Solutions Pty Ltd, Kurraba Group, Lachesis Biosciences Ltd, Nova Eye Medical, PureCDM, Syngene International Ltd, Viral Vector Manufacturing Facility.

Our warmest welcome to the following companies. We're so pleased you have joined AusBiotech and our community of more than 3000 life sciences leaders. We can't wait to work with you and your teams. 

AusBiotech's new members include:

• Agriculture Victoria Services Pty Ltd (AVS) is a specialist, professional entity responsible for protecting and commercialising novel technologies created by the Agriculture Victoria Research branch (AVR) of the Department of Energy, Environment and Climate Action (DEECA). AVS maximises the commercial value and impact of Agriculture Victoria research & innovation, so that Victorian agriculture and related industries are strong, innovative, and sustainable.
• Atticus Medical Pty Ltd (Atticus) is a clinical-stage biotechnology company focused on developing new and improved treatments for infectious diseases. Atticus' priority is the development and commercialisation of these new medicines in high-income countries. Atticus works with its not-for-profit partner, Medicines Development for Global Health, to support the often-neglected diseases that affect people in high-, medium- and low-income countries.
• BlinkLab Limited (ASX.BB1) is a company founded by neuroscientists at Princeton University. Over the past several years they have fully developed a smartphone based diagnostic platform for autism, ADHD, schizophrenia, and other neurodevelopmental conditions. Their most advanced product is an autism diagnostic test that leverages the power of smartphones, AI and machine learning to deliver screening tests specifically designed for children as young as 18 months old.
• CAD-IT Australia has a vision to provide digital solutions for real-world business challenges. The aim is to achieve this by using the latest cutting-edge technologies, combined with superior services and extensive expertise. CAD-IT Australia believes it can help Australian manufacturing companies become more competitive in international markets and assist in streamlining and optimising the product development process, driving more innovation and new product introductions.
• Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue regeneration applications. Cambium's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics with a primary focus on ophthalmology. Cambium Bio's lead product candidate, Elate Ocular®, is being developed to address significant unmet medical needs in the treatment of dry eye disease. In addition, the Company's stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.
• Douglas Pharmaceuticals is a New Zealand success story – a family-owned pharmaceutical company with a reputation for high manufacturing standards, quality products and outstanding client service. Through contract development and manufacturing business, Douglas CDMO, offers expertise, unwavering attention, dedication, and leading technology. Douglas Pharmaceuticals partners with biotechnology and pharmaceutical companies to successfully bring their products to life and out to market.
• Evaluate designs and measures initiatives which preserve and enhance access to healthcare and other social services. Evaluate has two core interests: social policy, including healthcare, ageing and education; and the regulation of market competition, both domestically and in cross-border trade.
• Evithé Biotechnology aims to expand the global medicines toolbox by putting nature back into medicine. They are inspired by the way that plants have evolved over millions of years to defend themselves with a multi-target defence system. Evithé Biotechnology specialises in harnessing natures defence mechanisms for the production of novel botanical drugs to serve a global market.
• EZZ Life Sciences (ASX:EZZ) is a genomic life sciences company with a mission to improve quality of life and human health. EZZ has a focus on genomic research and development to address four key human health challenges: genetic longevity, human papillomavirus (HPV), helicobacter pylori, and weight management. EZZ is passionate about investing in the future of consumer health through the development and distribution of high-quality products via omnichannel models across Australia, New Zealand, China and worldwide.
• Global Pharma Solutions is composed of expert pharmaceutical professionals covering the ANZ, EU, US, and APAC jurisdictions. Collectively, they have more than 150 years of industry experience in global regulatory affairs, clinical development, quality, and pharmacovigilance across a broad range of products, including prescription (biotech products, stem cells, biologicals, biosimilars, small molecules, generics), OTC and complementary medicines, medical devices, and cosmetics. They provide clients with the highest quality support, practical assistance, and guidance through complex regulatory, clinical, quality, and pharmacovigilance requirements, all tailored to specific market needs.
• JAG Process Solutions is a process engineering leader, planning and implementing the most challenging of process plants and automation solutions for the pharmaceuticals and biotech industries as well as for the food industry.
• Kurraba Group is Australia's only exclusive life science focussed real estate development and investment management business. Kurraba offers an end-to-end approach, led by an experienced team in institutional property and complex development. They acquire, develop and manage innovative real estate assets serving the life sciences industry to make a positive impact that lasts.
• Lachesis BioSciences is a clinical-stage biotechnology company targeting dementia caused by Alzheimer's and Parkinson's disease. Lachesis Biosciences is developing LBIO-R32, a rivastigmine nasal spray for the treatment of mild to severe Alzheimer's disease dementia and mild to moderate Parkinson's disease dementia.
• Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary glaucoma treatment technologies. Used by eye surgeons in more than 100 countries globally, these technologies include iTrack™ minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications, and the Molteno3® glaucoma drainage device for cases of severe and complex glaucoma.
• PureCDM is committed to creating and maintaining high-quality clinical data to support the development of new medicines and devices. With more than 25 years of local and global cross-functional expertise, they specialize in customizing technology and putting clinical data front and center as the company's most valuable asset.
• Syngene International Ltd is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene's more than 6000 scientists offer both skills and the capacity to deliver great science, robust data security, and quality manufacturing, at speed, to improve time-to-market and lower the cost of innovation. Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including GSK, Zoetis and Merck KGaA.
• Viral Vector Manufacturing Facility VVMF is the first and only commercial manufacturing facility of its kind in Australia, uniquely integrated in the largest health, education, research, and innovation precinct in the country. Supported by a world-class clinical trial ecosystem, VVMF will in partnership design, develop and manufacture viral vector solutions for companies, customers and patients.

Become a member of AusBiotech to strengthen your connections in the Australian life sciences industry, benefit from longstanding relationships across government, industry and academia, and shape advocacy efforts and help foster a sustainable and globally competitive sector.